Περίληψη:
Hepatitis C virus (HCV) is a major global public health issue, with an
estimated 71 million people living with HCV infection and a rising
burden of cirrhosis, hepatocellular carcinoma (HCC) and liver-related
mortality. The advent of interferon-free, direct acting antiviral-based
(DAA) therapies, with short duration (8-12 weeks), high efficacy,
excellent tolerability and ease of delivery (once daily oral dosing), is
one of the major advances in clinical medicine in recent decades, and
provides the opportunity to address this growing global HCV burden. In
May 2014, January 2015 and December 2015, three supplements were
published in the Journal of Viral Hepatitis presenting data from 47
countries on the historical epidemiology of HCV, the current HCV-related
morbidity and mortality and potential strategies to manage the HCV
disease burden in the future. The countries included in those
manuscripts were from multiple regions including North and South
America, Europe, Asia, the Middle East, Africa and Oceania. In this
supplement, data from an additional 17 countries are presented,
following a similar pattern as in the previous manuscripts. These
countries represent a mixture of high-, middle-and low-income countries
that hail from five geographical regions: Africa, Asia, Europe, Middle
East and South America. Expert advisory panels were convened in each
country to identify the best data sources to use and to review the
assumptions and outputs from the model. In the countries considered in
the current analyses, there is a wide variance in the availability of
robust data.
Συγγραφείς:
Dore, G. J.
Hatzakis, A.
Negro, F.
Waked, I.
